Analysts See $-0.61 EPS for Concert Pharmaceuticals, Inc. (CNCE); Mercadolibre (MELI) Shorts Lowered By 13.42%

April 15, 2018 - By Adrian Mccoy

MercadoLibre, Inc. (NASDAQ:MELI) Logo

Mercadolibre Inc (NASDAQ:MELI) had a decrease of 13.42% in short interest. MELI’s SI was 2.69M shares in April as released by FINRA. Its down 13.42% from 3.11M shares previously. With 600,500 avg volume, 5 days are for Mercadolibre Inc (NASDAQ:MELI)’s short sellers to cover MELI’s short positions. The SI to Mercadolibre Inc’s float is 6.12%. The stock increased 0.69% or $2.27 during the last trading session, reaching $329.67. About 972,608 shares traded or 47.37% up from the average. MercadoLibre, Inc. (NASDAQ:MELI) has risen 66.47% since April 15, 2017 and is uptrending. It has outperformed by 54.92% the S&P500.

Analysts expect Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) to report $-0.61 EPS on May, 1.They anticipate $0.01 EPS change or 1.67% from last quarter’s $-0.6 EPS. After having $-0.26 EPS previously, Concert Pharmaceuticals, Inc.’s analysts see 134.62% EPS growth. The stock decreased 1.34% or $0.27 during the last trading session, reaching $19.84. About 240,581 shares traded. Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) has risen 26.05% since April 15, 2017 and is uptrending. It has outperformed by 14.50% the S&P500.

Investors sentiment increased to 2.62 in Q4 2017. Its up 1.44, from 1.18 in 2017Q3. It improved, as 10 investors sold Concert Pharmaceuticals, Inc. shares while 19 reduced holdings. 42 funds opened positions while 34 raised stakes. 15.49 million shares or 6.32% more from 14.57 million shares in 2017Q3 were reported. Bogle Invest Mngmt Limited Partnership De holds 0.55% or 292,010 shares. Jane Street Gp Ltd Com holds 17,421 shares. Aqr Capital Mgmt Ltd Company holds 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 162,739 shares. 14,318 are held by Clarivest Asset Limited Liability Corp. Numeric Invsts Limited Liability Corp invested in 8,000 shares or 0% of the stock. Strs Ohio invested in 28,000 shares. Moreover, State Street Corp has 0% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for 291,652 shares. Federated Investors Pa stated it has 21,923 shares. Citadel Ltd Liability has invested 0% of its portfolio in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Moreover, Bvf Il has 6.14% invested in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Massachusetts-based Geode Capital Mgmt Ltd Liability Company has invested 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Wellington Mgmt Grp Inc Limited Liability Partnership accumulated 0% or 21,540 shares. Bankshares Of New York Mellon Corporation accumulated 0% or 198,192 shares. Northern Trust stated it has 0% in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Knott David M owns 49,557 shares for 0.51% of their portfolio.

Since October 19, 2017, it had 1 buying transaction, and 5 sales for $2.87 million activity. Shares for $372,402 were sold by ALDRICH RICHARD on Thursday, January 25. $5.26 million worth of stock was bought by BVF PARTNERS L P/IL on Thursday, October 19.

Among 9 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Concert Pharmaceuticals had 24 analyst reports since August 12, 2015 according to SRatingsIntel. As per Tuesday, September 22, the company rating was maintained by TH Capital. The company was maintained on Thursday, June 29 by Aegis Capital. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by H.C. Wainwright on Friday, November 10. The stock of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) earned “Buy” rating by UBS on Tuesday, December 19. Aegis Capital maintained the stock with “Buy” rating in Monday, June 12 report. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, October 19. H.C. Wainwright maintained the shares of CNCE in report on Monday, September 18 with “Buy” rating. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. Mizuho downgraded the shares of CNCE in report on Friday, January 12 to “Neutral” rating. The firm has “Buy” rating by Stifel Nicolaus given on Friday, January 12.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company has market cap of $460.95 million. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. It has a 4.88 P/E ratio. The company's clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis.

MercadoLibre, Inc. hosts online commerce platforms in Latin America. The company has market cap of $14.56 billion. It offers MercadoLibre Marketplace, an automated online commerce service for businesses and individuals to list items and conduct their sales and purchases online in a fixed-price or auction format. It has a 1063.45 P/E ratio. The companyÂ’s Marketplace platform enables commerce through online classifieds for motor vehicles, vessels, aircraft, services, and real estate; and Internet users to browse through various products that are listed on its Website and to register with MercadoLibre to list and purchase items and services.

Among 15 analysts covering MercadoLibre (NASDAQ:MELI), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. MercadoLibre had 43 analyst reports since August 6, 2015 according to SRatingsIntel. Stifel Nicolaus maintained it with “Hold” rating and $27500 target in Friday, August 4 report. The stock has “Overweight” rating by Barclays Capital on Wednesday, July 19. The rating was maintained by Stifel Nicolaus on Thursday, October 6 with “Hold”. The rating was maintained by J.P. Morgan with “Hold” on Wednesday, August 9. The stock has “Neutral” rating by Susquehanna on Monday, December 5. The firm has “Buy” rating by Stifel Nicolaus given on Friday, February 23. The firm has “Neutral” rating given on Monday, May 16 by JP Morgan. The stock has “Neutral” rating by Goldman Sachs on Tuesday, August 9. The firm earned “Buy” rating on Friday, August 25 by Stifel Nicolaus. JP Morgan upgraded the shares of MELI in report on Friday, September 2 to “Overweight” rating.

MercadoLibre, Inc. (NASDAQ:MELI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts

>